Accueil>>Lipids>> P450>>Dafadine-A

Dafadine-A

Catalog No.GC35803

Dafadine-A, un analogue de la dafadine, est un nouvel inhibiteur du cytochrome P450 DAF-9 chez le nématode Caenorhabditis elegans ; inhibe également l'orthologue mammifère du DAF-9 (CYP27A1).

Products are for research use only. Not for human use. We do not sell to patients.

Dafadine-A Chemical Structure

Cas No.: 1065506-69-5

Taille Prix Stock Qté
10mM (in 1mL DMSO)
52,00 $US
En stock
5mg
46,00 $US
En stock
10mg
68,00 $US
En stock
50mg
271,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Dafadine-A, an analog of dafadine, is a novel inhibitor of DAF-9 cytochrome P450 in the nematode Caenorhabditis elegans; also inhibits the mammalian ortholog of DAF-9(CYP27A1). IC50 value:Target: DAF-9(CYP27A1) inhibitorThe DAF-9 cytochrome P450 is a key regulator of dauer formation, developmental timing and longevity in the nematodeCaenorhabditis elegans. Here we describe the first identified chemical inhibitor of DAF-9 and the first reported small-molecule tool that robustly induces dauer formation in typical culture conditions. This molecule (called dafadine) also inhibits the mammalian ortholog of DAF-9(CYP27A1), suggesting that dafadine can be used to interrogate developmental control and longevity in other animals.

[1]. Luciani GM, et al. Dafadine inhibits DAF-9 to promote dauer formation and longevity of Caenorhabditis elegans. Nat Chem Biol. 2011 Nov 6;7(12):891-3.

Avis

Review for Dafadine-A

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dafadine-A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.